



**Link**

**Pharma-Chem Ltd.**

An ISO - 9001 Company

**REGD. OFFICE & FACTORY :**

Plot No. 161/1, 162,  
G.I.D.C., Nandesari-391 340.  
Dist. Baroda (Gujarat) (INDIA)  
Tal. (91) (0265)3065000  
Telefax : (91) (0265) 2841351  
E-mail : linkpharmachem@hotmail.com

Date: 28.01.2019

To,  
Department of Corporate Services,  
BSE Limited  
25<sup>th</sup> Floor, P J Towers,  
Dalal Street,  
Mumbai – 400 001

**Scrip Code: 524748**

Dear Sir/Madam,

**Sub: Unaudited Financial Results under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and nine months ended December 31, 2018.**

Pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board has at its meeting held on today approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2018.

Please find enclosed herewith Unaudited Financial Results along with Limited Review Report for the quarter and half year ended on December 31, 2018.

The meeting of Board of Directors commenced at 01:30 p.m. and concluded at 03:00 p.m.

You are requested to take the same on record.

Thanking you,

Yours faithfully,  
For Link Pharma Chem Ltd.

Bhushan Joshi  
Company Secretary



Encl: As above

**ADMN. OFFICE:** 504, Centre Point, R. C. Dutt Road, Alkapuri, Vadodara – 390 005

**Website:** www.linkpharmachem.co.in

**CIN:** L24230GJ1984PLC007540



**Link**

**Pharma Chem Ltd.**  
AN ISO - 9001 Company

**ADMN. OFFICE :**  
504, Centre Point,  
R.C. Dutt Road, Alkapuri,  
Baroda - 390 005.  
Phone No. 2357595  
E-mail : linkpharmachem@hotmail.com

LINK PHARMA CHEM LTD.

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2018

SR. NO.	PARTICULARS	(RS. IN LAKHS)					
		Quarter ended			Nine Month Ended		Year ended on
		31.12.2018 Un-Audited	30.09.2018 Un-Audited	31.12.2017 Un-Audited	31.12.2018 Un-Audited	31.12.2017 Un-Audited	31.03.2018 Audited
<b>1</b>	<b>Income</b>						
	[a] Revenue from Operation	607.98	819.27	635.12	1,975.91	1,875.08	2,396.44
	[b] Other Income	6.13	-6.71	0.04	8.05	0.04	6.95
	<b>Total Income 1(a+b)</b>	<b>614.12</b>	<b>812.56</b>	<b>635.16</b>	<b>1,983.96</b>	<b>1,875.12</b>	<b>2,403.39</b>
<b>2</b>	<b>Expenses</b>						
	Cost of Materials consumed	436.31	381.17	236.32	1,142.91	590.21	782.94
	Change in Inventories of finished goods work in progress	(151.37)	76.27	(41.44)	(89.02)	190.55	206.73
	Excise duty	-	-	-	-	41.50	43.21
	Employee benefit expenses	79.88	86.55	110.92	232.68	233.51	489.78
	Finance Costs	8.38	9.10	10.03	26.37	35.47	61.56
	Depreciation and amortisation expenses	21.55	21.55	20.73	64.58	62.17	85.95
	Other expenditure	152.89	178.43	224.00	453.99	591.61	596.17
	<b>Total Expenses</b>	<b>547.64</b>	<b>753.06</b>	<b>560.56</b>	<b>1,831.51</b>	<b>1,745.02</b>	<b>2,266.34</b>
<b>3</b>	<b>Profit before tax (1-2)</b>	<b>66.48</b>	<b>59.50</b>	<b>74.60</b>	<b>152.45</b>	<b>130.10</b>	<b>137.05</b>
<b>4</b>	<b>Tax expenses</b>						
	Current Tax	14.56	13.04	13.82	32.70	24.40	27.56
	MAT Credit Recognised	-	-	-	-	-	(39.53)
	Deferred Tax	-	-	-	-	-	35.54
<b>5</b>	<b>Profit for the year (3-4)</b>	<b>51.92</b>	<b>46.45</b>	<b>60.78</b>	<b>119.75</b>	<b>105.70</b>	<b>113.48</b>
<b>6</b>	<b>Other Comprehensive Income (Net of Tax)</b>						
	Items that will not be reclassified to Profit or Loss	2.12	4.25	-	6.37	-	7.14
	Income tax effect of the above	(0.41)	(0.82)	-	(1.23)	-	(1.95)
	<b>Total Comprehensive Income for the period</b>	<b>1.71</b>	<b>3.43</b>	<b>-</b>	<b>5.14</b>	<b>-</b>	<b>5.19</b>
<b>7</b>	<b>( Net of Tax) (5+6)</b>	<b>53.64</b>	<b>49.88</b>	<b>60.78</b>	<b>124.90</b>	<b>105.70</b>	<b>118.67</b>
<b>8</b>	<b>Paid up Equity share capital</b>	<b>444.05</b>	<b>444.05</b>	<b>444.05</b>	<b>444.05</b>	<b>444.05</b>	<b>444.05</b>
	( Face Value of each share of Rs. 10/- each)						
<b>9</b>	<b>Reserves excluding Revaluation Reserve as per balance sheet of previous year</b>						<b>534.89</b>
<b>10</b>	<b>Earnings Per Share</b>						
	Basic and diluted (in Rs.)	<b>1.21</b>	<b>1.12</b>	<b>1.37</b>	<b>2.81</b>	<b>2.38</b>	<b>2.56</b>

Notes :

- These Financial Results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on 28th January, 2019. The Statutory Auditors have carried out the limited review.
- The Company's operation fall under single segment namely "Chemicals" for the purpose of Indian Accounting standard (Ind As 108) on Segment Reporting.
- Consequent to implementation of the Goods and Service Tax ( GST) with effect from July 1, 2017, presentation of revenue for the quarters after that date excludes GST and not comparable with prior periods which includes Excise Duty.

PLACE: Vadodara  
DATE : 28.01.2019



For and behalf of the Board of  
Link Pharma Chem Ltd.

*S. G. Thakur*  
S. G. Thakur  
Managing Director


S -16 C, India Bulls Mega Mall, Dinesh Mill Road, Near Jetalpur Flyover, Akota, Vadodara - 390 007.  
(O) : 0265-2983872, (M) : 98254 83162, E-mail : sanjaysoni@gmail.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF  
INTERIM FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
LINK PHARMA CHEM LIMITED**

- 1 We have reviewed the accompanying statement of standalone Unaudited financial Results of LINK PHARMA CHEM LTD. ("the Company"), for the Quarter and Nine Months ended December 31, 2018 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting standard 34 "Interim Financial Reporting" ("Ind As 34"), prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
- 2 We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 3 Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian 'Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as modified by circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SANJAY SONI & ASSOCIATES  
Chartered Accountants  
FRN 113251W

  
CA Sanjay Soni  
Partner  
M.No. 040616



Place : Baroda  
Date : 28.1.2019